Short Interest in Stealth BioTherapeutics Corp (NASDAQ:MITO) Increases By 103.5%

Stealth BioTherapeutics Corp (NASDAQ:MITOGet Rating) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totalling 377,300 shares, an increase of 103.5% from the August 15th total of 185,400 shares. Based on an average daily trading volume, of 531,300 shares, the days-to-cover ratio is presently 0.7 days.

Stealth BioTherapeutics Stock Performance

NASDAQ:MITO opened at $0.32 on Friday. Stealth BioTherapeutics has a 1 year low of $0.16 and a 1 year high of $1.51. The firm has a 50 day moving average of $0.28 and a 200-day moving average of $0.36. The stock has a market capitalization of $18.97 million, a P/E ratio of -0.61 and a beta of 1.64.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $1.50 price objective on shares of Stealth BioTherapeutics in a report on Thursday, June 16th.

About Stealth BioTherapeutics

(Get Rating)

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies.

Read More

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with's FREE daily email newsletter.